Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives
- PMID: 7641363
- DOI: 10.1161/01.cir.92.4.825
Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives
Abstract
Background: Angiotensin-converting enzyme (ACE) inhibitors do not decrease plasma angiotensin (Ang) II levels 24 hours after drug intake to the same extent as at peak. This intermittent partial "escape" is explained either by a renin-mediated reactive rise in plasma Ang I or by non-ACE-dependent Ang II generation. We therefore tested the hypothesis that a combination of ACE inhibition and Ang II blockade may have additive biological and hemodynamic effects.
Methods and results: In a single-dose, double-blind, randomized, four-way, crossover study, an Ang II antagonist (losartan 50 mg), an ACE inhibitor (captopril 50 mg), their combination, and matched placebos were orally administered to 12 normotensive male volunteers maintained in mild sodium depletion. When captopril 50 mg and losartan 50 mg were given alone, the magnitude of their effects on blood pressure, plasma active renin, Ang I, and aldosterone was similar, whereas the kinetics of their effects were different, reflecting differences in drug pharmacokinetics. The losartan-captopril combination completely suppressed the rise in plasma Ang II induced by losartan 2 hours after drug intake (3.3 +/- 3.6 pg/mL versus 20.3 +/- 19.1 pg/mL, respectively, P < .05). Six hours after drug intake, the losartan-captopril combination induced a significantly greater decrease in mean blood pressure than that produced by either losartan or captopril alone (73 +/- 7 mm Hg versus 79 +/- 8 mm Hg versus 81 +/- 7 mm Hg, respectively, P < .05). The maximum placebo-subtracted falls in mean blood pressure for the losartan-captopril combination, captopril 50 mg, and losartan 50 mg were 14 +/- 5 mm Hg, 10 +/- 3 mm Hg, and 9 +/- 6 mm Hg, respectively (F2.22 = 3.45, P < .05). The duration of the mean blood pressure fall was not prolonged by the combination. After combined losartan-captopril administration, the area under the plasma active renin versus time curve (0 to 24 hours) was significantly increased when compared with either losartan or captopril alone (6404 +/- 2961 pg.h.mL-1 versus 3105 +/- 1461 pg.h.mL-1 versus 2092 +/- 867 pg.h.mL-1, respectively, P < .05). The combination had no additive effects on plasma aldosterone decrease when compared with either losartan or captopril alone (58 +/- 17% versus 51 +/- 20% versus 53 +/- 21%, respectively, NS).
Conclusions: The combined administration of a standard single oral dose of an ACE inhibitor and an Ang II antagonist to mildly sodium-depleted normal subjects (1) had a major additive effect on plasma renin rise, (2) induced an additional mean blood pressure reduction, and (3) had no additive effect on plasma aldosterone fall.
Similar articles
-
Additive effects of losartan and enalapril on blood pressure and plasma active renin.Hypertension. 1997 Feb;29(2):634-40. doi: 10.1161/01.hyp.29.2.634. Hypertension. 1997. PMID: 9040450 Clinical Trial.
-
Pharmacological demonstration of the additive effects of angiotensin-converting enzyme inhibition and angiotensin II antagonism in sodium depleted healthy subjects.Clin Exp Hypertens. 1997 Jul-Aug;19(5-6):937-51. doi: 10.3109/10641969709083197. Clin Exp Hypertens. 1997. PMID: 9247766 Clinical Trial.
-
Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man.Clin Sci (Lond). 1996 Mar;90(3):205-13. doi: 10.1042/cs0900205. Clin Sci (Lond). 1996. PMID: 8777826 Clinical Trial.
-
Blockade of the renin-angiotensin system at different sites: effect on renin, angiotensin and aldosterone.J Hypertens Suppl. 1993 Apr;11(3):S23-6. J Hypertens Suppl. 1993. PMID: 8315514 Review.
-
Pharmacology of angiotensin converting enzyme inhibitors. A review.Am J Med. 1986 Oct 31;81(4C):13-8. doi: 10.1016/0002-9343(86)90939-3. Am J Med. 1986. PMID: 3022580 Review.
Cited by
-
Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents.J Clin Invest. 2010 Apr;120(4):1229-39. doi: 10.1172/JCI39345. Epub 2010 Mar 24. J Clin Invest. 2010. PMID: 20335663 Free PMC article.
-
Intensified inhibition of renin-angiotensin system: a way to improve renal protection?Curr Hypertens Rep. 2007 Nov;9(5):430-6. doi: 10.1007/s11906-007-0078-3. Curr Hypertens Rep. 2007. PMID: 18177592 Review.
-
Angiotensin II receptor blockers and bone fracture in chronic kidney disease patients: the Fukuoka kidney disease Registry Study.Clin Exp Nephrol. 2023 Nov;27(11):919-927. doi: 10.1007/s10157-023-02385-3. Epub 2023 Jul 27. Clin Exp Nephrol. 2023. PMID: 37498346
-
Hypothesis: Reactive increases in plasma renin activity attenuate the fall in blood pressure caused by salt depletion and renin-angiotensin system inhibition.J Hypertens. 2025 May 1;43(5):739-746. doi: 10.1097/HJH.0000000000003964. Epub 2025 Feb 7. J Hypertens. 2025. PMID: 39976184 Free PMC article.
-
Angiotensin II: a new therapeutic option for vasodilatory shock.Ther Clin Risk Manag. 2018 Jul 26;14:1287-1298. doi: 10.2147/TCRM.S150434. eCollection 2018. Ther Clin Risk Manag. 2018. PMID: 30100727 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous